i could be wrong, but i'm under the impression tha
Post# of 145561
i believe that our market focus is NASH and cancer, per Cyrus (although that could change i suppose with a new CEO). so i was talking about the need to create data in those areas - and we don't have any real trial data (just preliminary and really small trial sample sizes) - hence the focus on starting a new NASH trial as they highlighted in the last call.
i do agree with you that our drug works in HIV, and it is a crying shame what happened with Amarex and the BLA process. My holdings would be worth a lot of money if that process had been handled correctly. oh well.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)